AbbVie and Bristol Myers Squibb are two of the largest pharmaceutical companies in the United States, yet they present investors with meaningfully different risk-and-reward profiles. Both are navigating the transition away from aging blockbusters toward newer medicines, making this a useful stock comparison for those weighing growth momentum against valuation. Income-oriented investors may find the dividend profiles relevant, while growth-focused traders may be more interested in the pace of new-drug launches and pipeline catalysts. This article examines recent business developments, relative performance, and market positioning to help readers understand how these two healthcare leaders stack up in the current environment.
AbbVie (ABBV) is a diversified biopharmaceutical company with strengths in immunology, oncology, neuroscience, and aesthetics. Its recent market activity has reflected confidence in its post-Humira strategy. After losing U.S. exclusivity for Humira — its former top-selling arthritis drug — AbbVie has leaned heavily on Skyrizi and Rinvoq, two newer immunology medicines that have grown rapidly and now anchor the portfolio.
In recent quarters, AbbVie reported double-digit revenue growth, driven by strong demand for these drugs alongside contributions from neuroscience products such as Vraylar and the newer Parkinson's therapy Vyalev. Management has raised its annual earnings guidance and increased its quarterly dividend by 5.5%, signaling conviction in sustained cash generation. The company has also been an active acquirer, pursuing deals and licensing agreements to broaden its pipeline. Areas of softness include declining Imbruvica sales and weaker demand for aesthetics products such as Botox, though these have not derailed the broader growth narrative.
Bristol Myers Squibb (BMY) is a global biopharmaceutical company with a leading position in oncology, along with franchises in hematology, cardiovascular, and immunology. Its recent performance has been more mixed. The company's "Growth Portfolio" — headlined by immuno-oncology drug Opdivo, plus Reblozyl, Camzyos, and CAR T-cell therapy Breyanzi — has posted strong sales increases, and the newly approved schizophrenia drug Cobenfy offers a new growth avenue.
However, these gains have been partially offset by generic competition eroding legacy products such as Revlimid, Pomalyst, Sprycel, and Abraxane. Eliquis, the company's top-selling blood thinner co-marketed with Pfizer, remains a key contributor but faces a potential patent cliff later this decade. In recent months, Bristol Myers has received several analyst upgrades citing pipeline momentum, and it announced a modest dividend increase. Still, the stock's valuation remains discounted relative to peers, reflecting ongoing uncertainty about how quickly new launches can replace declining legacy revenue.
Tickeron's Trending AI Robots page showcases a curated selection of automated trading strategies designed to adapt to shifting market conditions. Tickeron maintains hundreds of AI trading bots that collectively monitor thousands of different tickers, but only the best-performing and most suitable strategies for the current environment earn a place in this section. These bots vary widely in trading style, strategy, timeframe, risk profile, and the specific tickers they trade, giving investors a range of options to match their own objectives. Because the selection is refreshed to reflect prevailing market dynamics, the page serves as a useful starting point for those seeking data-driven, systematic approaches to the market. Explore Trending AI Robots to review the current lineup.
The clearest contrast between these two stocks is the stage of their respective patent-cliff transitions. AbbVie has largely absorbed the Humira decline and returned to solid top-line growth, while Bristol Myers Squibb is still working to offset meaningful erosion in its legacy franchise. This difference is reflected in relative performance: AbbVie's shares have shown stronger momentum, while BMY trades at a lower forward earnings multiple that prices in execution risk.
In terms of business model, both companies are diversified drugmakers, but their growth drivers differ. AbbVie's momentum is concentrated in immunology and neuroscience, whereas BMY's is anchored in oncology and hematology, with an emerging psychiatry opportunity in Cobenfy. Risk factors also diverge: AbbVie faces pricing-policy scrutiny and softer aesthetics demand, while BMY confronts steeper generic headwinds and near-term patent exposure. Sentiment has favored AbbVie recently, while BMY has attracted a mix of upgrades and cautious "hold" ratings as investors weigh pipeline potential against near-term revenue pressure.
Based on observable factors such as trend consistency, stability, and catalyst positioning, Tickeron's AI would likely favor AbbVie over Bristol Myers Squibb in the current environment. AbbVie's stronger relative performance, clearer post-patent-cliff earnings trajectory, and more robust dividend growth suggest steadier momentum. Bristol Myers Squibb offers a compelling valuation and genuine pipeline catalysts, but its transition appears earlier-stage and carries more execution uncertainty. Accordingly, an AI-driven assessment would lean toward AbbVie on a risk-adjusted basis, while acknowledging that BMY's discounted valuation could appeal to investors with a higher tolerance for uncertainty and a longer time horizon.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ABBV saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 03, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 27 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 57%.
The 10-day RSI Indicator for ABBV moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 18 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 42%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABBV as a result. In 36 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 47%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +0.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 222 of 361 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
ABBV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 217 of 349 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-86.736) is very low in comparison to the industry average of (-1.421). ABBV has a moderately high P/E Ratio (82.291) as compared to the industry average of (21.700). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.038) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 16 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
BMY moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend. In 32 of 44 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 73%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BMY as a result. In 56 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 62%.
The Moving Average Convergence Divergence Histogram (MACD) for BMY turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 27 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 55%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for BMY crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Following a +1.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in 175 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
BMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 151 of 217 cases where BMY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating fairly steady price growth. BMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.687) is normal, around the industry mean (-1.421). P/E Ratio (13.627) is within average values for comparable stocks, (21.700). BMY's Projected Growth (PEG Ratio) (17.786) is slightly higher than the industry average of (5.738). Dividend Yield (0.041) settles around the average of (0.038) among similar stocks. P/S Ratio (2.642) is also within normal values, averaging (4.033).
ABBV | BMY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 90 | 84 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 94 Overvalued | |
PROFIT vs RISK RATING 1..100 | 2 | 71 | |
SMR RATING 1..100 | 1 | 22 | |
PRICE GROWTH RATING 1..100 | 16 | 50 | |
P/E GROWTH RATING 1..100 | 92 | 64 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV's Valuation (4) in the Pharmaceuticals Major industry is significantly better than the same rating for BMY (94). This means that ABBV’s stock grew significantly faster than BMY’s over the last 12 months.
ABBV's Profit vs Risk Rating (2) in the Pharmaceuticals Major industry is significantly better than the same rating for BMY (71). This means that ABBV’s stock grew significantly faster than BMY’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as BMY (22). This means that ABBV’s stock grew similarly to BMY’s over the last 12 months.
ABBV's Price Growth Rating (16) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (50). This means that ABBV’s stock grew somewhat faster than BMY’s over the last 12 months.
BMY's P/E Growth Rating (64) in the Pharmaceuticals Major industry is in the same range as ABBV (92). This means that BMY’s stock grew similarly to ABBV’s over the last 12 months.
| ABBV | BMY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 42% | N/A |
| Stochastic ODDS (%) | 2 days ago 69% | 2 days ago 57% |
| Momentum ODDS (%) | 2 days ago 47% | 2 days ago 62% |
| MACD ODDS (%) | 2 days ago 57% | 2 days ago 55% |
| TrendWeek ODDS (%) | 2 days ago 49% | 2 days ago 55% |
| TrendMonth ODDS (%) | 2 days ago 64% | 2 days ago 57% |
| Advances ODDS (%) | 11 days ago 61% | 11 days ago 57% |
| Declines ODDS (%) | 3 days ago 47% | 3 days ago 54% |
| BollingerBands ODDS (%) | 2 days ago 62% | 2 days ago 64% |
| Aroon ODDS (%) | 2 days ago 62% | 2 days ago 70% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green while BMY’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 4 TA indicator(s) are bullish while BMY’s TA Score has 5 bullish TA indicator(s).
ABBV (@Pharmaceuticals: Major) experienced а -2.99% price change this week, while BMY (@Pharmaceuticals: Major) price change was -7.30% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -12.82%. For the same industry, the average monthly price growth was -9.89%, and the average quarterly price growth was -5.74%.
ABBV is expected to report earnings on Feb 03, 2027.
BMY is expected to report earnings on Feb 04, 2027.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with NVS. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then NVS could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +0.94% | ||
| NVS - ABBV | 52% Loosely correlated | -0.50% | ||
| BMY - ABBV | 51% Loosely correlated | +0.79% | ||
| JNJ - ABBV | 51% Loosely correlated | +1.25% | ||
| AMGN - ABBV | 49% Loosely correlated | -0.15% | ||
| GILD - ABBV | 47% Loosely correlated | -0.06% | ||
More | ||||
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.